Quote:

---

AVXL had good results for the Alzheimer's IIb/3 clinical trial, statistically significant improvements. Their drug does not target dissolving amyloid plaques, it's trying to stop the disease further upstream before the plaques form.

---

Anavex's drug blarcamesine activates Sigmar1. The main thing Sigmar1 does is downregulation of calcium signaling, the downstream effects include stopping mitochondrial dysfunction and lowering some inflammatory factors. Leronlimab of course also regulates calcium signaling via downregulation of intracellular calcium. Blocking CCR5 though would control a much broader array of factors affecting inflammation and mitochondrial dysfunction.